WO1994024268A1 - Vecteur d'adenovirus de recombinaison avien - Google Patents

Vecteur d'adenovirus de recombinaison avien Download PDF

Info

Publication number
WO1994024268A1
WO1994024268A1 PCT/AU1994/000189 AU9400189W WO9424268A1 WO 1994024268 A1 WO1994024268 A1 WO 1994024268A1 AU 9400189 W AU9400189 W AU 9400189W WO 9424268 A1 WO9424268 A1 WO 9424268A1
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
avian adenovirus
vector
nucleotide sequence
fav
Prior art date
Application number
PCT/AU1994/000189
Other languages
English (en)
Inventor
Michael Sheppard
Katrina Erny
Richard Mccoy
Wendy Werner
Original Assignee
Arthur Webster Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthur Webster Pty. Ltd. filed Critical Arthur Webster Pty. Ltd.
Priority to AU64994/94A priority Critical patent/AU676042B2/en
Priority to JP52254294A priority patent/JP3606870B2/ja
Priority to EP94912411A priority patent/EP0690912B1/fr
Priority to DE69435081T priority patent/DE69435081T2/de
Publication of WO1994024268A1 publication Critical patent/WO1994024268A1/fr
Priority to US09/272,032 priority patent/US6296852B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • This invention relates to delivery vectors for antigen producing genes (heterologous gene sequences) used to generate immune responses in commercial poulty flocks susceptible to decimation by disease. Such vectors are especially useful for the preparation of vaccines which can be easily administered on a large scale to protect poultry flocks against disease.
  • This invention also relates to a method of production of suitable delivery vectors, to methods of preparation of vaccines based on the vectors, to administration strategies and to a method of protecting poultry from disease.
  • the invention provides, in one embodiment, a recombinant avian adenovirus capable of expressing DNA of interest, said DNA of interest being stably integrated into an appropriate site of said recombinant avian adenovirus genome.
  • the invention provides a recombinant vector comprising a recombinant avian adenovirus which incorporates at least one heterologous nucleotide sequence.
  • the heterologous nucleotide sequence is capable of expression as an antigenic polypeptide.
  • the antigenic polypeptide encoded by the at least one nucleotide sequence is preferably foreign to the host vector.
  • the recombinant vector may comprise a live recombinant avian adenovirus in which the virion structural proteins are unchanged from those in the native avian adenovirus from which the recombinant avian adenovirus is produced.
  • the invention is predicated upon the discovery that certain regions of the Fowl Adenovirus have unique properties.
  • the major late promoter and leader sequences are quite dissimilar to equivalent regions in Adenoviruses previously characterised. It has surprisingly been discovered that the leader sequence is a dipartite leader sequence. It is also surprising, based on knowledge of human adenoviruses that there are non-essential regions in the fowl Adenovirus genome which do not correspond to those characterised previously in other Adenoviruses thus making this virus particularly suited to delivery of heterologous sequences.
  • This invention is further predicated on the discovery that the Avian adenovirus generates a prolonged response in poultry thus making it well suited as a vaccine vehicle. Furthermore, the existence of a number of serotypes of varying virulence allows the selection of a vaccine vehicle suited to the level of immune response required.
  • Adenoviruses are a large and diverse family, having been isolated from many living species, including man and other mammals, as well as a variety of birds, particularly chickens (Wigand, R., Gelderblom, H. and Ozell, M. Biological and Biophysical characteristics of mouse adenovirus, strain FL. Arch, Virol. 54: 131 -142; 1977). As a result adenoviruses have been separated into two different genera, one group has a mammalian host range (Mastadenoviradae) and the other an avian host range (Aviadenoviradae).
  • avian adenovirus serotypes are only very distantly related to mammalian adenoviruses a knowledge of the latter is only partially instructive in relation to the former.
  • the avian adenoviruses show only very limited DNA homology with human adenoviruses (Alestrom, P., Stenlund, A., Li, P., Belief, A.J.D. and Pettersson, U. Sequence homology between avian and human adenoviruses. J. Virol. 42: 306- 310; 1982) with fowl adenovirus (“FAV”) genomes being some 10 kilobases larger than the human adenovirus genome.
  • FAV fowl adenovirus
  • the classification of these viruses as adenoviruses is based solely on morphological and structural similarities.
  • the genus Aviadenovirus is currently divided into 5 species groups; fowl, turkey, goose, pheasant and duck adenoviruses.
  • Fowl adenoviruses were first recognized in the 1950s when they were isolated as a consequence of using embryonated eggs and cell cultures infected with FAV (Van Den Ende, M., Don, P.A. and Kipps, A. The isolation in eggs of a new filterable agent which may be the cause of bovine lumpy skin disease. J. gen. Micro. 3: 174-182; 1949; Yates, V.J. and Fry, D.E.
  • CELO chicken embryo lethal orphan virus
  • HAV human adenoviruses
  • CELO virus is composed of at least 11 -14 structural proteins (Yasue, H. and Ishibashi, M. Chick embryo lethal orphan (CELO) virus-induced early and late polypeptides. Virol. 78:216-233; 1977; Li, P., Belief, A.J.D. and Parish, C.R. DNA-binding proteins of chick embryo lethal orphan virus: Lack of complementation between early proteins of avian and human adenoviruses. J. gen. Virol. 65: 1817-1825; 1984a) and is structurally similar to HAV which is composed of 10-14 structural proteins (Maizel, J.V. (Jr.), White, D.O. and Scharff, M.
  • the polypeptides of adenovirus I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A and 12. Virol. 36: 115-125; 1968; Ishibashi, M. and Maizel, (Jr.), J.V. The polypeptides of adenovirus V. Young virions, structural intermediate between top components and aged virions. Virol. 57:409-424; 1974). The only morphological difference apparent between them is the additional FAV fibre. Even allowing for a second fibre gene a considerable amount of 'excess' DNA remains to be accounted for in the genome of FAV when compared to the HAV.
  • RNA binding protein (DBP) (Li, P., Bellet, 5 A.J.D. and Parish, C.R. DNA-binding proteins of chick embryo lethal orphan virus: Lack of complementation between early proteins of avian and human adenoviruses. J. gen. Virol. 65: 1817-1825; 1984a).
  • DBP DNA binding protein
  • VA RNAs from avian and human adenoviruses dramatic differences in length, sequence, and gene location. J.Virol. 58: 600- 609; 1986).
  • DBP of FAV which initiates transcription by interacting with the E1 A genes, fails to recognize the E1 A genes of HAV (Li, P., Bellet, A.J.D. 0 and Parish, C.R. DNA-binding proteins of chick embryo lethal orphan virus: Lack of complementation between early proteins of avian and human adenoviruses. J. gen. Virol. 65: 1817-1825; 1984a).
  • Fowl adenoviruses are common within poultry flocks, and to date 11 distinct serotypes have been recognized (McFerran, J.B. and Connor, T.J. Further studies on the classification of fowl adenoviruses. Av. Dis. 21 :585-595; 1977). While all of these serotypes appear to be widely disseminated throughout the world, epidemiological surveys show that in a given geographical location certain serotypes appear to predominate. For example, in America the most common serotypes encountered are 1 ,4,5,7 and 9 (Cowen , B., Mitchell, G.B. and Cainek, B.W. An adenovirus survey of poultry flocks during the growing and laying periods. Av.
  • a further consideration is the ability of the vector to remain active in the bird beyond the period within which maternal antibodies protect the bird immediately post-hatching.
  • FAV vectors should be highly infectious but non-pathogenic (or at least stably attenuated) such that they do not themselves adversely affect the target species.
  • pathogenicity or at least stably attenuated
  • Preferred candidates for use as vaccine vectors are non-pathogenic isolates FAV CFA20 (serotype 10), and CFA15 (serotype 10).
  • the CFA20 virus is the more preferred vector candidate because it is clinically safe and because it represents a serotype apparently uncommon in Australian and American poultry flocks. This is an important consideration as it reduces the possible problems associated with prior exposure.
  • FAV CFA15 and CFA19 (serotype 9) are also suitable candidates worthy of consideration for vector development.
  • Other serotypes may also be useful. It is notable that more virulent strains produce a greater antibody response.
  • Heterologous nucleotide sequences which may be incorporated into non- essential regions of the viral genome and which may encode the antigenic determinants of infectious organisms against which the generation of antibodies or cell-mediated immunity is desirable may be those expressing antigenic determinants of intestinal infections caused by parasites; for example, coccidial infections or respiratory viruses, for example, infectious bronchitis virus.
  • Other infectious organisms against which immunity may be desirable include those that target internal organs such as the bursa of Fabricius, for example, infectious bursal disease virus (IBDV).
  • Heterologous nucleotide sequences which may be incorporated include the antigenic determinants of the agents of
  • Heterologous nucleotide sequences more preferred for incorporation in the vectors of the invention are those expressing antigenic determinants of infectious bursal disease (VP2) and coccidiosis.
  • heterologous sequences incorporated may be immunopotentiator molecules such as cytokines or growth promoters, for example chicken myelomonocytic growth factor (cMGF) or insulin like growth factors (IGF).
  • cytokines for example chicken myelomonocytic growth factor (cMGF) or insulin like growth factors (IGF).
  • IGF insulin like growth factors
  • the type of immune response stimulated by candidate vectors may affect the selection of heterologous nucleotide sequences for insertion therein.
  • FAV isolates CFA20 and CFA15 may induce mucosal immunity and are thus more suitable for infections of the intestines or respiratory system.
  • FAV isolates such as CFA19 which induce a strong serum antibody response may be more suitable for use against diseases of the organs of poultry because of their ability to penetrate beyond the gut of the bird.
  • the DNA of interest which may comprise heterologous genes coding for antigenic determinants or immuno potentiator molecules may be located in at least one non-essential region of the viral genome.
  • Non-essential regions of the viral genome which may be suitable for the purposes of replacement with or insertion of heterologous nucleotide sequences may be non-coding regions at the right terminal end of the viral genome.
  • this region is located at the right end of the genome at map units 97 to 99.9.
  • the heterologous gene sequence may be associated with a promoter and leader sequence in order that the nucleotide sequence may be expressed in situ as efficiently as possible.
  • the heterologous gene sequence is associated with the avian adenoviral major late promoter and splice leader sequence.
  • the major late promoter lies near 16-17 map units on the adenovirus genetic map and contains a classical TATA sequence motif. (Johnson, D.C., Ghosh-Chondhury, G., Smiley, J.R., Fallis, L and Graham, F.L. (1988). Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector. Virology 164, 1-14).
  • the splice leader sequence of the avian adenovirus isolates under consideration is a dipartite sequence spliced to late genes.
  • the heterologous gene sequence may also be associated with a poly adenylation sequence.
  • avian adenoviral major late promoter any other suitable eukaryotic promoter can be used.
  • SV40 virus cytomegalovirus (CMV) or human adenovirus
  • CMV cytomegalovirus
  • human adenovirus may be used.
  • Processing and poly adenylation signals other than those of avian adenoviruses may also be considered, for example, that of SV40.
  • a recombinant vaccine for generating and/or optimising antibodies or cell mediated immunity so as to provide or enhance protection against infection with an infectious organism in birds, the vaccine comprising at least one recombinant avian adenovirus vector incorporating at least one heterologous nucleotide sequence formulated with suitable carriers and excipients.
  • the nucleotide sequence is capable of expression as an antigenic polypeptide.
  • the antigenic polypeptide encoded by the at least one nucleotide sequence is preferably foreign to the host vector.
  • At least one nucleotide sequence may be associated with a promoter/leader and a poly A sequence.
  • the recombinant vaccine may include live recombinant avian adenovirus vector in which the virion structural protein are unchanged from that in the native avian adenovirus from which the recombinant avian adenovirus is produced.
  • Preferred vector candidates for use in the recombinant vaccine are FAV isolates CFA20 (serotype 10), CFA15 (serotype 10) and CFA19 (serotype 9). Use of other serotypes is possible, depending on the poultry type, its existing immunity and its environment.
  • the vaccine may be directed against respiratory and intestinal infections caused by a variety of agents.
  • heterologous gene sequences encoding the antigenic determinants of those infectious organisms may be incorporated into non- essential regions of the genome of the avian adenovirus comprising the vector.
  • suitable heterologous nucleotide sequences may be those of immunopotentiators such as cytokines or growth promoters.
  • the vaccines may comprise other constituents, such as stabilisers, excipients, other pharmaceutically acceptable compounds or any other antigen or part thereof.
  • the vaccine may be in the form of a lyophilised preparation or as a suspension, all of which are common in the field of vaccine production.
  • a suitable carrier for such a vaccine may be isotonic buffered saline.
  • a method of preparing a vaccine for generation and/or optimisation of antibodies or cell- mediated immunity so as to induce or enhance protection against an infectious organism in a bird which comprises constructing a recombinant avian adenovirus vector incorporating at least one heterologous nucleotide sequence, and placing said recombinant avian adenovirus vector in a form suitable for administration.
  • the nucleotide sequence is capable of expression as an antigenic polypeptide although it may also be an immunopotentiator.
  • the nucleotide sequence is conveniently foreign to the host vector.
  • nucleotide sequence is associated with promoter/leader and poly A sequences.
  • the form of administration may be that of an enteric coated dosage unit, an inoculum for intra-peritoneal, intramuscular or subcutaneous administration, an aerosol spray, by intraocular drop or intranasal application. Administration in the drinking water, in feed pellets or in ovo is also possible.
  • the more preferred mode of administration is as an aerosol spray.
  • a method of producing an avian adenovirus vaccine vector which comprises inserting into an avian adenovirus at least one heterologous nucleotide sequence.
  • Said heterologous nucleotide sequence is preferably capable of expression as an antigenic polypeptide.
  • the antigenic polypeptide encoded by the at least one nucleotide sequence is foreign to the host vector. More preferably the heterologous nucleotide sequence is associated with promoter/leader and poly A sequences.
  • a restriction enzyme site preferably being one that does not cleave the host genome selected for construction, is inserted into a non-essential and preferably non-coding region of the host genome.
  • the recombinant viral genome thus is provided with a unique restriction enzyme site in a non-essential region to allow insertion of heterologous nucleotide sequences by simple restriction enzyme cleavage and ligation.
  • This method has the added advantage of enabling, if preferred, deletion of portions of the non-essential region to allow the insertion of greater portions of DNA.
  • a DNA expression cassette containing an appropriate FAV promoter with a foreign gene sequence as well as leader sequences and poly adenylation recognition sequences can be constructed with the unique restriction enzyme sites flanking the cassette enabling easy insertion into the
  • the non- essential region to be altered to incorporate foreign DNA could be constructed via homologous recombination.
  • the non-essential region is cloned, a portion of it is deleted and foreign DNA together with promoter, leader and poly adenylation sequences is inserted preferably by homologous recombination between flanking sequences.
  • deletion of portions of the non-essential region is possible to create extra room for larger DNA inserts that are beyond the normal packaging constraints of the virus.
  • strategies for administration of the vaccines of the invention are provided.
  • the vaccine is preferably administered by aerosol spray since airborne spread is a natural route of FAV dissemination.
  • FAV vector based vaccines may be administered as 'cocktails' comprising 2 or more virus vectors carrying different foreign genes or immunopotentiators.
  • the 'cocktail' or simultaneous strategy a vaccine based on both FAV isolates CFA19 and CFA20 is used.
  • FAV vector based vaccines may be administered consecutively of each other to either administer booster vaccines or new vaccines at some stage subsequent to initial FAV vaccination.
  • the vaccines used are preferably based on heterologous FAV isolates.
  • vaccines based on isolates serotypically unrelated are selected so as to achieve maximum protection against infection.
  • a vaccine based on FAV isolate CFA20 is administered subsequently or prior to vaccination with a vaccine based on FAV isolate CFA19.
  • Poultry are conveniently inoculated with vector vaccines according to the invention at any age. Where chickens are concerned, broilers may be vaccinated at 1 day old, breeders and layers may be vaccinated regularly up to point of lay and thereafter.
  • poultry are vaccinated while still not fully immunocompetent. More conveniently, day-old birds can be vaccinated for protection against re-infection after a period of 4 weeks subsequent to initial vaccination.
  • a method for producing an immune response in a bird comprising administering to the bird an effective amount of a recombinant vaccine according to the invention.
  • An effective amount as referred to throughout the present description is an amount sufficient to elicit an immune response, preferably at least 10 4 TCID 50 per dose, but within the range of 10 3 - 10 7 TCID 50 per dose depending on the method of application.
  • the vaccine of the invention may of course be combined with vaccines against other viruses or organisms such as Marek's Disease virus, Newcastle Disease virus or infectious bronchitis at the time of its administration.
  • administration is by aerosol spray.
  • Table 1 illustrates the suitability of several other isolates of varying serotype. Pathogenicity was tested by administration of 10 6 pfu of virus injected in a 0.5 ml volume via the intraperitoneal route. Surviving chickens were killed at 8-10 days and tissue samples taken for histology and virus re-isolation.
  • the genomes of the selected isolates FAV CFA15, 19 and 20 were characterised by conventional methods.
  • adenovirus genomes are normally oriented such that the terminal region from which no late mRNA transcripts are synthesised is located at the left end.
  • the enzyme used to generate each map is indicated at the edge of each map.
  • TATA sequence the only one in the region sequenced, as well as potential upstream factors and was subsequently confirmed by the location of the leader sequence and the transcriptional start site.
  • Figure 4 illustrates the sequence characterisation and cloning of the major late promoter and splice leader sequences of CFA20. Specifically, shown are the Hp ⁇ l and Dr ⁇ l restriction endonuclease maps of FAV CFA20. The regions cloned ( ⁇ ⁇ ) and sequenced ( — ) are indicated.
  • RNAzol B solution (Bresatec, Australia). The isolated RNA was precipitated with isopropanol and stored at -70°C in 50 ⁇ l aliquots until required.
  • Poly A (mRNA) was isolated from total RNA by the use of the Poly AT tract System (Promega, USA). The isolated mRNA was used in cDNA production.
  • oligonucleotides were produced to the complementary strand of the hexon gene and the penton base gene, both being MLP transcripts. A further oligo was produced which covered the proposed cap site of the major late transcript, 24 bases downstream of the TATA box. This oligonucleotide was used in conjunction with that used in cDNA production in Taq polymerase chain reaction. The resulting DNA produced from positive clones was digested with appropriate restriction enzymes to determine the size
  • SUBSTTTUTE SHEET (Rule 26) of the inserted fragment.
  • DNA sequencing of these inserted fragments was performed using a modification of the chain termination technique (Sanger, F., Nicklen, S. and Gulson, A.R. (1977) DNA sequencing with chain terminating inhibitors PNAS USA 74: 5463-5467) so as to allow T7 DNA polymerase extension (Pharmacia, Sweden).
  • cDNA was incubated with 1 mM dGTP and approximately 15 units of terminal deoxynucleotidyl transferase (Pharmacia) in 2 mM CaCI 2 buffer at 37°C for 60 minutes. The reaction was stopped by heating to 70°C for 10 minutes. The DNA was then ethanol precipitated and resuspended in a volume suitable for use in polymerase chain reaction (PCR). PCR was performed as previously described using a poly (dC) oligonucleotide with a Xbal site at the 5' end. Resulting fragments were digested with Xbal and Smal and cloned into pUCI9 vector. DNA preparation and sequencing were performed, as described previously, on clones shown to be positive by hybridization.
  • PCR polymerase chain reaction
  • Figure 5 illustrates the DNA sequence of the major late promoter, upstream enhancer sequences and splice leaders 1 and 2 showing the arrangement of splice leader 1 from cDNA studies.
  • FAV serotype 10 CFA 20 NdeI/3 fragment of 4249 bp.
  • the entire organisation of genes in the right end (contained in the Ndel/3 fragment) of FAV appears to be very different to other adenoviruses that have been characterised.
  • This region contains two open reading frames terminating by base 3361 (Fig. 6). This leaves a relatively large region of 824 bp that is available for deletion and insertion of foreign DNA. This will allow at least 3.1 map units of previously unidentified and unexpected DNA for deletion and therefore insertion.
  • Figure 6 illustrates an expanded region from 92-100 map units for the
  • FAV CFA20 genome shows the non-coding region available for deletion of virus DNA and insertion of heterologous DNA. Also indicated are possible coding regions.
  • Figure 7 illustrates a preferred method of construction of a FAV vector.
  • the right hand end Ndel fragment 3 of the FAV CFA20 is cloned and a unique restriction endonuclease (NotI) site is inserted.
  • CK cells were transfected with purified altered Ndel fragment 3 and purified Spel fragment 1 to produce a functional virus by homologous recombination with a unique restriction endonuclease (NotI) site in the genome.
  • One particularly preferred FAV isolate is that identified as FAV M11 NotI which was deposited at the Australian
  • Figure 8 illustrates construction of an expression cassette for FAV.
  • the major late promoter and splice leader sequences 1 and 2 are inserted into a plasmid vector as well as multiple cloning sites for insertion of foreign DNA and a poly A recognition site. All these are flanked by unique restriction endonuclease recognition sequences (NotI) for insertion into the unique restriction endonuclease site in the FAV genome.
  • the IBDV vp2 gene was inserted into the expression cassette as described in Figure 8.
  • the expression cassette was isolated as a NotI fragment and cloned into the unique NotI site previously engineered into the FAV NdeI/3 fragment.
  • the plasmid containing the vp2 gene was linearised and transfected together with FAV Spell , DNA into CK cells. This plasmid was deposited at the Australian Government Analytical Laboratories on 1 1 March 1994 and can be identified in the bacterium E.coli DH52 pFMLP 234. This bacterium has been given the accession number N94/8878. 2. Construction of a FAV thymidine kinase recombinant
  • TK Infectious Laryngotracheitis Virus
  • ILTV Infectious Laryngotracheitis Virus
  • TK expression cassette was isolated as a NotI fragment ( Figure 8) and cloned into the unique NotI site previously engineered into the FAV NdeII3 fragment ( Figure 7).
  • FAV vectors expressing the TK gene were selected by passage through methatrexate, a metabolic inhibitor that blocks the replication of TK deficient (wild type) viruses. Southern blot hybridisation, following plaque purification, confirmed the presence of the TK gene within the NdeI/3 fragment of the resulting FAV vector. The ability to isolate a FAV-TK recombinant by passage through methatrexate, clearly demonstrates the potential to insert, and express, foreign genes within this region of the FAV genome. EXPRESSION OF FOREIGN GENES
  • Figures 9 and 10 illustrate the use of expression cassettes of FAV to express foreign genes.
  • Various constructions containing either the FAV MLP/LS with or without upstream sequences (USS), a transcriptional start site, multiple cloning site and a poly A recognition sequence were tested for expression of the chloramphenicol acetylase (CAT) gene or the vp2 antigen gene from infectious bursal disease virus (Azad, A.A., Fahey, K.J., Barrett, S.A., Erny, K.M. and Hudson, P.J. (1986) Expression in Escherichia coli of cDNA Fragments encoding the gene for the host protective antigen of infectious bursal disease virus. Virology 1 49 190-198).
  • CAT chloramphenicol acetylase
  • Vaccine comprising one vector
  • day old chicks were used to represent immuno- incompetent birds and 3 week old chickens as representative of chickens approaching immunocompetency.
  • Day-old chicks were infected with CFA20 by aerosol spray.
  • Virus was suspended in sterile isotonic saline at a dose of 5x1 0 7 /chicken.
  • the birds were placed into a confined area and the virus sprayed into the air at the head height of the birds such that the spray contacted the eyes and beaks of the chickens.
  • the coarse spray was delivered using a pump-action plastic spray bottle.
  • the onset of serum antibody responses were monitored by ELISA and virus neutralization assays. The detailed results are shown in Table 2.
  • Virus was recovered from caecal tonsils for 4 weeks post-infection, the disappearance of virus coinciding with the development of circulating antibody which could be detected by ELISA but not by the virus neutralization assay. No virus neutralizing antibodies were detected over the 7 week period of this experiment. However, attempts to re-infect these chicks with CFA20 at 6 weeks after the primary infection were unsuccessful as reflected by the failure to recover virus and the absence of an anamnestic ELISA antibody response in the serum. When chickens were infected at 3 weeks of age virus could be recovered for only 1-2 weeks postinfection, and again the clearance of virus coincided with development of antibodies detectable by ELISA (Table 3).
  • Virus neutralizing antibodies could also be detected in the serum of these chickens but not before 4 weeks post-infection (7 weeks of age). This was 2 weeks after the clearance of virus from the caecal tonsils. 2. Administration of Consecutive Vaccines
  • Chickens were vaccinated with a recombinant fowl adenovirus carrying the gene for VP2 of infectious bursal disease virus (IBDV) or with CFA20. Birds 5 were bled at 0 and 14 days and then weekly after the intraperitoneal administration of the vaccine at one day old. Sera were collected and tested for the presence of antibody against VP2 of IBDV and adenovirus by ELISA. The results in Table 6 show that antibody against VP2 was first detected in the group vaccinated with the recombinant, 14 days after vaccination and peaked at 28 0 days post-vaccination.
  • IBDV infectious bursal disease virus
  • the birds vaccinated with CFA20 did not have detectable antibody 5 against VP2.
  • Anti-adenovirus antibody was detected at 14 days post vaccination in both groups. 5. Induction of protection by the Administration of a recombinant vaccine
  • Chickens were vaccinated intravenously either with the recombinant 0 adenovirus carrying the IBDV VP2 gene or with the CFA20. Both groups were challenged with virulent infectious bursal disease virus 21 days after vaccination. All birds were killed 4 days later and IBDV in the bursa of

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un vecteur de recombinaison comprenant un adénovirus de recombinaison avien qui renferme et qui est capable d'exprimer au moins une séquence nucléotidique hétérologue. De préférence cette séquence nucléotidique est du type de celle qui code un déterminant antigénique du virus de la maladie infectieuse des bourses séreuses. Cette invention concerne également un procédé de production de vecteurs de recombinaison, des procédés de préparation de vaccins avec ces vecteurs, ainsi que des stratégies d'administration et des procédés permettant de protéger les volailles contre les maladies.
PCT/AU1994/000189 1993-04-14 1994-04-14 Vecteur d'adenovirus de recombinaison avien WO1994024268A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU64994/94A AU676042B2 (en) 1993-04-14 1994-04-14 Recombinant avian adenovirus vector
JP52254294A JP3606870B2 (ja) 1993-04-14 1994-04-14 組換えトリアデノウイルスベクター
EP94912411A EP0690912B1 (fr) 1993-04-14 1994-04-14 Vecteur d'adenovirus de recombinaison avien
DE69435081T DE69435081T2 (de) 1993-04-14 1994-04-14 Rekombinanter adenovirusvektor für geflügel
US09/272,032 US6296852B1 (en) 1993-04-14 1999-03-18 Recombinant avian adenovirus vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL829793 1993-04-14
AUPL8297 1993-04-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/272,032 Continuation-In-Part US6296852B1 (en) 1993-04-14 1999-03-18 Recombinant avian adenovirus vector

Publications (1)

Publication Number Publication Date
WO1994024268A1 true WO1994024268A1 (fr) 1994-10-27

Family

ID=3776839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1994/000189 WO1994024268A1 (fr) 1993-04-14 1994-04-14 Vecteur d'adenovirus de recombinaison avien

Country Status (5)

Country Link
EP (2) EP0690912B1 (fr)
JP (1) JP3606870B2 (fr)
DE (1) DE69435081T2 (fr)
NZ (1) NZ263772A (fr)
WO (1) WO1994024268A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040180A1 (fr) * 1996-04-20 1997-10-30 Boehringer Ingelheim International Gmbh Virus celo
FR2767335A1 (fr) * 1997-08-14 1999-02-19 Veterinaires Et Alimentaires C Adenovirus aviaire celo recombinant comme vecteur vaccinant
WO2000029444A1 (fr) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation d'anticorps par vaccination polynucleotidique dans le cas d'une espece aviaire
WO2001088162A2 (fr) * 2000-05-16 2001-11-22 Genway Biotech, Inc. Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations
EP1364205A1 (fr) * 2001-02-02 2003-11-26 Avigenics, Inc. Production d'un anticorps monoclonal par un oiseau transgenique
EP1523992A1 (fr) * 1996-07-19 2005-04-20 Merial Formules de vaccin contre la maladie de Gumboro
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
US10758608B2 (en) 2014-08-08 2020-09-01 Grupo Industrial Pecuario, S.A. De C.V. Vaccine in the form of a recombinant sero type 9 avian adenovirus vector
CN112646933A (zh) * 2021-01-21 2021-04-13 福建省农业科学院畜牧兽医研究所 鸭4型腺病毒实时荧光定量pcr检测引物、探针及试剂盒
CN114231503A (zh) * 2021-11-15 2022-03-25 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 鸡传染性法氏囊病病毒、血清4型禽腺病毒二联灭活疫苗及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150958A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156478A2 (fr) * 1984-02-13 1985-10-02 The University of Saskatchewan Propagation d'adéno(AA)virus aviaires du groupe II dans une culture de cellules aviaires et vaccin ainsi produit
AU562548B2 (en) * 1982-01-11 1987-06-11 Animal Vaccine Research Corp. Virus with recombinant surface proteins
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1490962A1 (ru) * 1987-06-17 1995-04-10 Институт Биохимии И Физиологии Микроорганизмов Ан Ссср Способ встраивания днк в геном аденовируса и рекомбинантный аденовирусный вектор celo/puc 19
JPH05501064A (ja) * 1990-05-04 1993-03-04 ユニバーシティ　オブ　メリーランド　アット　カレッジ　パーク Ｉｂｄｖタンパク質に関連する特異的ｄｎａ配列並びにベクター、宿主およびワクチン
WO1993003145A1 (fr) * 1991-07-26 1993-02-18 Virogenetics Corporation Vaccin de poxvirus recombinant obtenu a partir du virus de la bursite infectieuse
RU2031122C1 (ru) * 1992-09-07 1995-03-20 Владимир Иванович Грабко Способ встраивания гетерологичной днк в геном аденовируса celo и рекомбинантный аденовирусный вектор celo/рuc19
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU562548B2 (en) * 1982-01-11 1987-06-11 Animal Vaccine Research Corp. Virus with recombinant surface proteins
EP0156478A2 (fr) * 1984-02-13 1985-10-02 The University of Saskatchewan Propagation d'adéno(AA)virus aviaires du groupe II dans une culture de cellules aviaires et vaccin ainsi produit
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUNLIN ZHANG, ET AL.: "IDENTIFICATION AND CHARACTERIZATION OF VIRAL POLYPEPTIDES FROM TYPE-II AVIAN ADENOVIRUSES.", AMERICAN JOURNAL OF VETERINARY RESEARCH., AMERICAN VETERINARY MEDICINE ASSOCIATION, US, vol. 52., no. 07., 1 July 1991 (1991-07-01), US, pages 1137 - 1141., XP000607599, ISSN: 0002-9645 *
See also references of EP0690912A4 *
SHEPPARD M., TRIST H.: "CHARACTERIZATION OF THE AVIAN ADENOVIRUS PENTON BASE.", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 188., 1 June 1992 (1992-06-01), AMSTERDAM, NL, pages 881 - 886., XP000608409, ISSN: 0042-6822, DOI: 10.1016/0042-6822(92)90546-2 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773709B2 (en) 1996-04-20 2004-08-10 Boehringer Ingelheim International Gmbh Chicken embryo lethal (CELO) virus
WO1997040180A1 (fr) * 1996-04-20 1997-10-30 Boehringer Ingelheim International Gmbh Virus celo
US6335016B1 (en) 1996-04-20 2002-01-01 Boehringer Ingelheim International Gmbh Chicken embryo lethal orphan (CELO) virus
EP1523992A1 (fr) * 1996-07-19 2005-04-20 Merial Formules de vaccin contre la maladie de Gumboro
FR2767335A1 (fr) * 1997-08-14 1999-02-19 Veterinaires Et Alimentaires C Adenovirus aviaire celo recombinant comme vecteur vaccinant
WO1999009194A1 (fr) * 1997-08-14 1999-02-25 Agence Francaise De Securite Sanitaire Des Aliments Adenovirus aviaire celo recombinant et son utilisation comme vecteur vaccinant
WO2000029444A1 (fr) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation d'anticorps par vaccination polynucleotidique dans le cas d'une espece aviaire
US6951742B1 (en) 1998-11-16 2005-10-04 Genway Biotech, Inc. Methods and vectors for generating antibodies in avian species and uses therefor
WO2001088162A2 (fr) * 2000-05-16 2001-11-22 Genway Biotech, Inc. Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations
WO2001088162A3 (fr) * 2000-05-16 2002-09-19 Genway Biotech Inc Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations
EP1364205A4 (fr) * 2001-02-02 2004-11-24 Avigenics Inc Production d'un anticorps monoclonal par un oiseau transgenique
EP1364205A1 (fr) * 2001-02-02 2003-11-26 Avigenics, Inc. Production d'un anticorps monoclonal par un oiseau transgenique
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
US10758608B2 (en) 2014-08-08 2020-09-01 Grupo Industrial Pecuario, S.A. De C.V. Vaccine in the form of a recombinant sero type 9 avian adenovirus vector
CN112646933A (zh) * 2021-01-21 2021-04-13 福建省农业科学院畜牧兽医研究所 鸭4型腺病毒实时荧光定量pcr检测引物、探针及试剂盒
CN114231503A (zh) * 2021-11-15 2022-03-25 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 鸡传染性法氏囊病病毒、血清4型禽腺病毒二联灭活疫苗及其制备方法和应用

Also Published As

Publication number Publication date
DE69435081T2 (de) 2008-06-12
EP0690912A1 (fr) 1996-01-10
EP0690912A4 (fr) 1997-01-15
EP0690912B1 (fr) 2008-03-05
JPH08508410A (ja) 1996-09-10
NZ263772A (en) 1996-12-20
EP1650310A1 (fr) 2006-04-26
DE69435081D1 (de) 2008-04-17
JP3606870B2 (ja) 2005-01-05

Similar Documents

Publication Publication Date Title
US5187087A (en) Recominbant herpesvirus of turkeys and live vector vaccines derived thereof
RU2624037C2 (ru) Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла
US20100150958A1 (en) Methods and Compositions for Use of a Coccidiosis Vaccine
WO2010119112A1 (fr) Vecteurs du virus de l'herpès aviaire recombinant et vaccin pour immuniser les espèces de gibier d'eau
EP0728842B1 (fr) Vaccin vivant recombinant aviaire à base de virus herpès aviaire, notamment contre la maladie de gumboro
JP2021500876A (ja) 複数の異種抗原をコードする組換え非病原性マレック病ウイルス構築物
US6913751B2 (en) Recombinant avian herpesvirus useful in vaccine production
EP0690912B1 (fr) Vecteur d'adenovirus de recombinaison avien
CA2110505A1 (fr) Vaccin poxvirus recombinant contre le virus de la bursite infectieuse
CN109310750B (zh) 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体
US20100008948A1 (en) Recombinant herpesvirus useful in vaccine production
US6296852B1 (en) Recombinant avian adenovirus vector
US5279965A (en) Recombinant infectious laryngotracheitis virus
WO2003075843A2 (fr) Vaccins a base d'adn multiples et multivalents in ovo
AU676042B2 (en) Recombinant avian adenovirus vector
JPH07503843A (ja) マレック病ウイルス組換えポックスウイルスワクチン
US20170096644A1 (en) Ibv strains and uses thereof
WO1996021034A1 (fr) Vaccin vivant recombinant aviaire
JP3675569B2 (ja) 組み換えウイルス及びそれよりなるワクチン
JP2002095485A (ja) 広域スペクトルの伝染性ファブリキウス嚢病ウイルスワクチン
JP3693075B2 (ja) 組み換えウイルス、その作製法およびその利用
JPH07255488A (ja) 組換えマレック病ウイルスおよびその作出法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 448617

Date of ref document: 19950908

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 263772

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994912411

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994912411

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994912411

Country of ref document: EP